Skip to Main content Skip to Navigation
Journal articles

Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.

Abstract : To improve the targeting to tumors expressing the cholecystokinin receptor subtype 2 (CCK2R) with limited kidney uptake, we synthesized a novel cholecystokinin C-terminal tetrapeptide (CCK4)-based derivative conjugated to an original bipyridine-chelator (BPCA), 111In-BPCA-(Ahx)2-CCK4. To our knowledge this is the first CCK4-based radioligand that presents a high affinity for the CCK2R, a high and specific tumor uptake, a low renal accumulation and a very good visualization of tumors in vivo compared with an internal control, 111Indium-trans-cyclohexyldiethylenetriaminepenta-acetic acid-cholecystokinin octapeptide (111In-CHX-A''-DTPA-CCK8). These properties make 111In-BPCA-(Ahx)2-CCK4, a promising candidate for imaging and peptide receptor radionuclide therapy of CCK2R positive tumors.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-00519158
Contributor : Marc Poirot <>
Submitted on : Saturday, September 18, 2010 - 3:30:36 PM
Last modification on : Monday, June 29, 2020 - 2:18:02 PM

Identifiers

Collections

Citation

Séverine Brillouet, Sandra Dorbes, Frédéric Courbon, Claude Picard, Jean Pierre Delord, et al.. Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation.. Bioorganic and Medicinal Chemistry, Elsevier, 2010, 18 (14), pp.5400-12. ⟨10.1016/j.bmc.2010.05.031⟩. ⟨inserm-00519158⟩

Share

Metrics

Record views

464